HOGA1突变不导致以肾结石为表现的显性表型
本研究为观察性分析性病例对照研究,探讨HOGA1突变是否以显性形式导致草酸钙肾结石或高草酸尿症。在60例阿什肯纳兹犹太人和86例非阿什肯纳兹草酸钙结石患者中,突变携带率与对照组无差异(1.7% vs 2.8%,p=0.9),非阿什肯纳兹组未检出突变,且高草酸尿与HOGA1变异无相关性。结论认为HOGA1突变不赋予草酸钙肾结石或高草酸尿症的显性表型。
要点
- HOGA1突变携带者不表现为显性草酸钙肾结石病。
- 阿什肯纳兹犹太人携带率1.7%与对照2.8%无显著差异。
- 非阿什肯纳兹结石患者中未检出HOGA1突变。
核心结论
- HOGA1突变不导致以草酸钙肾结石或高草酸尿症为表现的显性表型。
研究设计与样本
- 观察性分析性病例对照研究,纳入60例阿什肯纳兹犹太人和86例非阿什肯纳兹草酸钙结石患者,以及150例低尿草酸和150例高尿草酸受试者。
- 对HOGA1基因进行Sanger测序,并与gnomAD相应 Ethnic 组数据比较52种致病突变的携带频率。
主要发现
- 阿什肯纳兹犹太人结石患者中致病突变携带率为1.7%,对照组为2.8%(p=0.9,OR=0.6,95%CI 0.01-3.51)。
- 非阿什肯纳兹结石患者组未检测到任何HOGA1突变。
- 未发现高草酸尿与HOGA1变异之间存在相关性。
临床怎么用
- 对于草酸钙肾结石患者,HOGA1突变检测不应作为常规病因筛查手段。
- 临床遇到高草酸尿症时,不应仅凭HOGA1杂合突变解释表型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The etiology of calcium-oxalate kidney stone formation remains elusive. Biallelic mutations in HOGA1 are responsible for primary hyperoxaluria type 3 and result in oxalate overproduction and kidney stone disease. Our previous study showed that carriers of HOGA1 mutations have elevated urinary levels of oxalate precursors. In this study we explored the possibility that mutations in HOGA1 confer a dominant phenotype in the form of kidney stone disease or hyperoxaluria. MATERIALS AND METHODS: An observational analytic case control study was designed to determine the prevalence of pathogenic HOGA1 mutations among adults with calcium-oxalate kidney stone disease. Given the high prevalence of HOGA1 mutations among Ashkenazi Jews, this group was evaluated separately. Carrier frequency of any of the 52 reported pathogenic mutations was compared to data derived from gnomAD for the corresponding ethnic group. Sanger sequencing of HOGA1 gene was performed on DNA samples from the following groups: 60 Ashkenazi Jews and 86 nonAshkenazi calcium-oxalate stone formers, 150 subjects with low and 150 with high urinary oxalate levels. RESULTS: The carrier prevalence of pathogenic mutations among the Ashkenazi Jews was 1.7% compared to 2.8% in the corresponding control group (p=0.9 OR=0.6 95% CI 0.01-3.51). We did not detect any mutation among the nonAshkenazi study group. No correlation was detected between hyperoxaluria and HOGA1 variants. CONCLUSIONS: This study shows that mutations in HOGA1 do not confer a dominant phenotype in the form of calcium-oxalate kidney stone disease or hyperoxaluria.
引用
- Bar R, Ben-Shalom E, Duvdevani M, et al. Mutations in HOGA1 do Not Confer a Dominant Phenotype Manifesting as Kidney Stone Disease. J Urol. 2020. PMID: 33350326. doi:10.1097/JU.0000000000001528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。